News
OCS
21.15
+13.10%
2.45
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Benzinga · 22h ago
Oculis Holding Is Maintained at Buy by Chardan Capital
Dow Jones · 4d ago
Oculis Holding Price Target Maintained With a $28.00/Share by Chardan Capital
Dow Jones · 4d ago
Chardan Capital Maintains Buy on Oculis Holding, Maintains $28 Price Target
Benzinga · 4d ago
Promising Clinical Results and Market Potential Drive Buy Rating for Oculis Holding
TipRanks · 4d ago
Oculis price target raised to $31 from $23 at BofA
TipRanks · 4d ago
Oculis Holding’s OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis
TipRanks · 4d ago
Oculis Holding Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $30 Price Target
Benzinga · 4d ago
Oculis Holding’s OCS-05 Receives Buy Rating Amid Promising Clinical Data and Regulatory Advancements
TipRanks · 4d ago
Bank of America Securities Sticks to Their Buy Rating for Oculis Holding (OCS)
TipRanks · 5d ago
Weekly Report: what happened at OCS last week (1230-0103)?
Weekly Report · 5d ago
Oculis' OCS-05 Reveals Phase 2 ACUITY Trial Results, Setting Pathway For First-In-Class Neuroprotective Therapy In Acute Optic Neuritis
Benzinga · 5d ago
Oculis Holding AG Reports Positive Phase 2 ACUITY Trial Results for OCS-05 as Potential Therapy for Acute Optic Neuritis
NASDAQ · 5d ago
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
Barchart · 5d ago
Oculis Publishes Notification of Major Changes in Voting Rights
Barchart · 01/03 17:48
Weekly Report: what happened at OCS last week (1223-1227)?
Weekly Report · 12/30/2024 09:52
Oculis Holding (OCS): A Biopharma Opportunity for Adventurous Investors
TipRanks · 12/26/2024 14:35
Weekly Report: what happened at OCS last week (1216-1220)?
Weekly Report · 12/23/2024 09:55
Weekly Report: what happened at OCS last week (1209-1213)?
Weekly Report · 12/16/2024 09:55
More
Webull provides a variety of real-time OCS stock news. You can receive the latest news about Oculis Holding through multiple platforms. This information may help you make smarter investment decisions.
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.